Treatment of hypertension in patients with type 2 diabetes: A review of the recent evidence

Journal of Human Hypertension

Volumn 13, Issue 12, 1999, Pages 803-811

  Chowdhury, Tahseen A ^a,b   Kumar, S ^a   Barnett, A H ^a   Dodson, P M ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Hypertension; Treatment; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE; DIABETIC MICROANGIOPATHY; DRUG CHOICE; DRUG EFFICACY; HEALTH CARE COST; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

EID: 0033392019     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000920     Document Type: Review

References (51)

1. Hypertension in Diabetes Study Group. Hypertension in diabetes study: I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11: 309-317.
2. Hypertension in Diabetes Study Group. Hypertension in diabetes study: II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993; 1: 319-325.
3. Janka HU, Dirschedl P. Systolic blood pressure as a predictor for cardiovascular disease in diabetes. A five year longitudinal study. Hypertension 1985; 7 (Suppl II): 90-94.
4. United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS 23). BMJ 1998; 316: 823-828.
5. Systolic Hypertension in the Elderley Program. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
6. Staessen JA et al. Randomised double-blind comparison of placebo versus active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-764.
7. Curb JD et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276: 1886-1892.
8. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
9. Hansson L et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
10. United Kingdom Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998; 317: 720-726.
11. United Kingdom Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
12. Tuomilehto J et al. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677-684.
13. Johnston J, Paterson KR, O'Reilly DS. Estimating urinary albumin excretion in clinical practice. BMJ 1993; 306: 493-494.
14. Niskanen L, Uusitupa M, Sarlund H. Microalbuminuria predicts the development of serum lipoprotein abnormalities favouring atherogenesis in newly diagnosed type 2 (non-insulin dependent) diabetic patients. Diabetologia 1990; 33: 237-243.
15. Agardh C-D et al. Greater reduction of urinary albumin excretion in hypertensive typo II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996; 10: 185-192.
16. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987; i: 581-584.
17. Alderman MH, Ooi WL, Madhavan S, Cohen H. Treatment induced blood pressure reduction and the risk of myocardial infarction. JAMA 1989; 262: 920-924.
18. Lindholm L, Ejlertsson G, Schersten B. High risk of cerebro-cardiovascular morbidity in well treated male hypertensives: a retrospective study of 40-59 year old hypertensives in a Swedish primary care district. Acta Med Scand 1984; 216: 251-259.
19. Mancia G et al. Blood pressure control in the hypertensive population. Lancet 1997; 349: 454-457.
20. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998; 16: 747-752.
21. Avanzini F, Marchioli R, Alli C, Tognoni G. Hypertension Optimal Treatment (HOT) trial. Lancet 1998; 352: 571-572.
22. Senderovitz T, Kampmann JP. Hypertension Optimal Treatment (HOT) trial. Lancet 1998; 352: 573.
23. Sever P et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 1993; 306: 983-987.
24. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356-362.
25. Wood D et al. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80 (Suppl 2): S1-S29.
26. Guidelines Subcommittee. 1999 World Health Organisation - International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-183.
27. Yudkin JS, Chaturvedi N. Developing risk stratification charts for diabetic and nondiabetic subjects. Diabetic Med 1999; 16: 219-227.
28. Warram JH et al. Excess mortality associated with diuretic therapy in diabetes mollitus. Arch Intern Med 1991; 151: 1350-1356.
29. Bloomgarden Z et al. Elevated hemoglobin A1c and low density lipoprotein cholesterol levels in thiazide treated diabetic patients. Am J Med 1984; 77: 823-827.
30. Micossi P et al. Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus. Horm Metab Res 1984; 16: 59-63.
31. Pahor M et al. Calcium channel blockade and incidence of cancer in aged populations, Lancet 1996; 348: 493-497.
32. Pahor M, Guralnik JM, Furburg CD. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996; 347: 1061-1065.
33. Zuicala G, Pahor M, Landi F. Use of calcium antagonists and need for peiroperative transfusion in older patients with hip fracture: observational study. BMJ 1997; 314: 643-644.
34. Lindberg G. Use of calcium channel blockers and risk of suicide: ecological findings confrimed in population based cohort study. BMJ 1998; 316: 741-745.
35. Psaty BM et al. The risk of myocardial infarction associated with anti-hypertensive drug therapies. JAMA 1995; 274: 620-625.
36. Estacio RO et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-652.
37. Poulter NR. Calcium antagonists and the diabetic patient: a response to recent controversies. Am J Cardiol 1998; 82: 40R-41R.
38. Tatti P et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diab Care 1998; 21: 597-603.
39. Parving HH. Calcium antagonists and cardiovascular risk in diabetes. Am J Cardiol 1998; 82: 42R-44R.
40. Borhani NO, Mercuri M, Borhani PA. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomised controlled trial. JAMA 1996; 276: 785-791.
41. Byington RP, Craven T, Furberg CD, Pahor M. Isradipine, raised glycosylated haemoglobin and risk of cardiovascular events. Lancet 1997; 350: 1075-1076.
42. United Kingdom Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720.
43. Hansson L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
44. Cutler J. Which treatment for hypertension? Lancet 1999; 353: 604-605.
45. Geiger H. Are angiotensin II receptor blockers superior to angiotensin coverting enzyme inhibitors with regard to their renoprotective effect? Nephrol Dial Transplant 1997; 12: 640-642.
46. Gall MA, Nielsen FS, Smidt UM, Parvinh HH. The course of kidney function in type 2 (non-insulin dependent) diabetic patients with diabetic nephropathy. Diabetologia 1993; 36: 1071-1078.
47. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995; 155: 1073-1080.
48. Gaede P, Vedel P, Parving H-H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-622.
49. Dodson PM et al. Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ 1989; 298: 227-230.
50. JNC. The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure (JNC-VI). Arch Intern Med 1997; 157: 2413-2446.
51. Davis BR et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996; 9: 342-360.